Opinion: Blue blood on the streets
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Copy Link URLCopied!
  • Print
  • X
  • LinkedIn
  • Email
© 2024 Insider International Limited, company number 15236286, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian Group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

Opinion: Blue blood on the streets

Mark Geoghegan
23 March 2018
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Copy Link URLCopied!
  • Print
  • X
  • LinkedIn
  • Email

If Lloyd's aggregate results were not already shock enough, yesterday's exclusive revelation that MS Amlin was a £1.4bn ($2bn) capacity outlier within that £33bn whole ripped down Lime Street like a lightning bolt.

Enter your e-mail to claim a free trial:

Uncover exclusive insights tailored for insurance leaders

    • Stay Informed: Access exclusive industry insights
    • Gain a competitive advantage: Hear first about tactical developments
    • Make better decisions: Understand market dynamics in crucial lines of business
Take a free trial Already a subscriber? Login now

Topics

NewsReinsurersM&AResults
Mark-Geoghegan_220-180.png
Mark Geoghegan
Gift this article